Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LPDX. In for bounce. "At March 25, 2014, 15,223,053 shares of LipoScience, Inc. Common Stock, $0.001 par value, were outstanding." with 60% institutional holding.
Overdone here. Bought some 3s
not a good developement the last weeks and today really down....watch up to now here what will happen..
MUST READ lPDX 50 bucks+ EoY
Laboratory Testing Companies
The $50 billion medical-lab-testing sector’s average profit margin is a healthy 8.2 percent, putting it just above restaurants and below oil and gas equipment and services. The mother of all lab-test companies, Quest Diagnostics, earned a 9.1 percent margin during the last year, just a hair behind Exxon Mobil. In April, defunct Quest subsidiary Nichols Institute Diagnostics pleaded guilty and paid a $40 million criminal fine for the felony misbranding of a test called the Nichols Advantage Chemiluminescence Intact Parathyroid Hormone Immunoassay. (With names like these, they could just as well charge you for their afternoon coffee and call it Post Meridien Genera Coffea Robusta on your bill.) Another $262 million was paid by Quest to settle other civil allegations. Despite the fines, Quest’s revenues were up 3.5 percent in the second quarter of 2009, to $1.9 billion, and its C.E.O., Surya Mohapatra, pulled down $11,964,632 in compensation last year.
MMakers love to make a stock look like a POS, take ur shares and then run it to the roof. If marijuana plays can go up 1000% watch this gem run like a scoulded dog soon. Put it away for a month, don't get shook out and wake up above 50 bucks imo....
cya
PCBI
NEW CEO w/CONNECTIONS!!!! MMakers trying their hardest to keep this under 5 bucks...Not for long. I predict 50 bucks min EOY. Qtrly earnings will be growing as R&D costs decline and marketing picks up with new connections. Get on the right side of the trade peeps.
http://finance.yahoo.com/news/liposcience-announces-appointment-howard-doran-130000866.html
Buyout by Roche Diagnostics trading 63.00 PPS imminent READ @ New CEO today!
8:01 am LipoScience appoints Howard Doran to President and Chief Executive Officer effective February 3, 2014 (LPDX) : Doran was most recently President & Chief Operating Officer of Constitution Medical, Inc., an early stage in vitro diagnostics company, developer of the Bloodhound Fully Integrated Hematology System, which was acquired by Roche Diagnostics (RHHBY) in July 2013.
Why 100-120 Bucks PPS EOY.....READ!!!!!!!!
New technology in cardiovascular LDL-P is the breakthrough technology that all labs will be using in the future. Doctors are beginning to be educated about the how the old LDL-C test is going to be obsolete. Medical technology advances are what make markets move.
Quest Diagnosics needs this technology. DGX 92.00 PPS
LPDX already has 51,000,000 revenues and 50,000,000 cash. Only trading in a float of 10,000,000.
As the restructuring of research and development costs decline the contract/sales for this technology will grow internationally.
Recent news regarding Scripps out of California is just the beginning.
ENJOY THE RIDE!!!!!!! The volume will through this crazy above 100 and vaporize the float with a real company new technology already making millions in a niche market...
SMILING @ 100+
http://www.liposcience.com/about-liposcience/our-technology
1/8/2013 PPS 4.50
Buy 10,000 shares and put them away for 11 Months
cya EOY 60-100 bucks!!! (0r buyout from ABT, DGX for 50.00)
BYE
50 bucks EOY MARK THIS POST
LPDX a winner peeps!
I suspect we see double digits on news of new CEO hire
Huge opportunity for LT gains here. Unlike pharma this isn't a speculative investment. More like a Blue Chip of pharma imo
is this guy the guy gettn 45,000 a month? Sounds like a good officer to add to this company for shareholder value!
9:01AM LipoScience announces appointment of William Cromwell as Chief Medical Officer (LPDX) 5.09 : Co announced the appointment of William Cromwell as Chief Medical Officer. Dr. Cromwell joins LipoScience from the Lipoprotein and Metabolic Disorders Institute in Raleigh, North Carolina.
$LPDX ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!
$LPDX has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~
What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~
To find other similar posts of "LPDX" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "LPDX": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=LPDX ~
Search Ihub for "LPDX" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=LPDX ~
For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~
Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~
Keeps going down....ugh
8:05AM LipoScience guides Q2 revs in line with the low end of previous guidance, lowers FY13 rev guidance; appoints Robert Greczyn Interim President and CEO (LPDX) 6.43 : Co issues downside guidance for Q2 (Jun), sees Q2 (Jun) revs of $13.3 mln vs. $13.74 mln Capital IQ Consensus Estimate (Co said the $13.3 mln is in line with the low end of the guidance provided during the Company's first quarter 2013 earnings conference call).
Co issues lowered guidance for FY13 (Dec), sees FY13 (Dec) revs of $52-54 mln from prior guidance of $54-56 mln vs. $55.37 mln Capital IQ Consensus Estimate.
Co also announced that Richard Brajer has stepped down as President, CEO and Director to pursue other interests. Robert Greczyn has been named Interim President & Chief Executive Officer, effective immediately. The Board of Directors of LipoScience intends to initiate a search for a permanent CEO immediately.
Nice bounce off bottom. Great time to buy as this will continue to rise.
On the brighter side. Company is on the right track.
LipoScience's Vantera® Clinical Analyzer To Provide Hospitals And Physicians With Lipoprotein Analysis For Cardiovascular Di...
RALEIGH, N.C., May 22, 2013 /PRNewswire/ -- LipoScience, Inc., (NASDAQ: LPDX) a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care, today announced availability of NMR lipoprotein particle testing using the Vantera® Clinical Analyzer through Mayo Medical Laboratories.
NMR lipoprotein testing on the Vantera Clinical Analyzer will be accessible to Mayo Clinic physicians and patients and other hospital clients of Mayo Medical Laboratories. The Vantera Clinical Analyzer can identify and quantify concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. This analysis provides physicians and patients with a detailed assessment of cardiovascular disease (CVD) risk from a single blood test that measures the concentration of low-density lipoprotein particles (LDL-P) and other lipoprotein information.
LDL-P is the first FDA-cleared assay on the Vantera Clinical Analyzer and is a key component of LipoScience's NMR LipoProfile® test. To date, over 9 million NMR LipoProfile tests have been ordered to aid in CVD risk management. Adoption and decentralization of the Vantera Clinical Analyzer into clinical laboratories will ultimately provide widespread access to the NMR LipoProfile test, reduce sample processing turnaround time and provide value to physicians focused on delivering quality patient care and personalized management of cardiovascular disease.
"LDL-P improves the identification of patients at risk for cardiovascular disease risk compared to calculated LDL cholesterol," said Allan Jaffe, MD, a clinical cardiologist and Professor of Medicine and Laboratory Medicine and Pathology at the Mayo Clinic. Amy Saenger, Ph.D. is the Director of Cardiovascular Laboratory Medicine at Mayo Clinic and stated "We are excited to offer LDL-P and other NMR lipoprotein profiles, enhancing our extensive and expanding cardiovascular disease test menu." Mayo Medical Laboratories and the Cardiovascular Laboratory will continue their close scientific collaboration with LipoScience to develop new NMR-based assays targeted at improving outcomes for patients with CVD.
"Having Mayo Medical Laboratories offer NMR lipoprotein particle testing within Mayo Clinic and to external physicians is an important milestone as we drive towards widespread adoption and availability of the NMR LipoProfile test, to personalize the management of patients with cardiovascular disease risk," said Tim Fischer, Chief Operating Officer at LipoScience.
About LipoScience, Inc.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the FDA. It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk away automation. The Vantera system will be placed with national and regional clinical laboratories.
LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com.
About Mayo Clinic Department of Laboratory Medicine and Pathology/Mayo Medical Laboratories
The Department of Laboratory Medicine and Pathology at Mayo Clinic maintains an active diagnostic test development program, incorporating Mayo Clinic discoveries and expertise with discoveries from other diagnostic and biotechnology companies and leading academic and research organizations. Mayo uses these proven diagnostic technologies to care for its own patients and offers them to more than 5,000 health care institutions around the world through Mayo Medical Laboratories. Revenue from testing is used to support medical education and research at Mayo Clinic. For more information, visit www.MayoMedicalLaboratories.com.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.com and www.mayoclinic.org/news.
Forward Looking Statements
The statements in this press release that are not historical facts constitute "forward-looking statements" that involve risks and uncertainties and are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements include expectations regarding the capabilities and availability of the Vantera Clinical Analyzer, LipoScience's collaboration with the Mayo Clinic and the Company's ability to increase and sustain demand for its NMR LipoProfile test, as well as the Company's plans for future diagnostic tests on the Vantera platform. The achievement or success of the matters covered by such forward-looking statements involve risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, the Company's results could differ materially from the results expressed or implied by the forward-looking statements it makes. These risks and uncertainties include, but are not limited to, risks associated with the receptiveness of third-party laboratories with respect to the placement of Vantera Clinical Analyzers at their facilities, the Company's ability to expand its sales and marketing capabilities in order to increase demand for the NMR LipoProfile test and any future tests that it may develop, the Company's ability to compete with other diagnostic testing methods that may be more widely accepted and the Company's ability to secure regulatory clearance by the FDA of the non-cleared portions of the NMR LipoProfile test. Further information on these and other factors that could affect the Company's results is included in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations page of the Company's website at http://investor.liposcience.com. The statements made in this release are based on information available to LipoScience as of the date of this release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Big drop in pps was from Deerfield Management.
I assume they do not have enough sales reps to cover all the medical areas to move to the better NMR LipoProfile tests. Eventually this will change by just word of mouth.
"We are dissatisfied with our unit growth and revenue performance, and our responses are already underway," commented Richard Brajer, President and Chief Executive Officer. "Based on a comprehensive review, the four primary factors contributing to the first quarter 2013 revenue shortfall were 1) we were unable to get the needed number of new sales representatives up and running, 2) our direct business is converting to our lab partners at a faster rate than prior years, 3) managed care headwinds, and 4) Vantera system placement delays."
"Given these factors and our slow start, we are reducing our full year 2013 revenue guidance to $54 to $56 million," said Mr. Brajer. "Unfortunately, these issues cannot be fixed overnight. But I can assure you that we fully understand what the issues are, and we are assertively implementing our responses as we continue to drive toward becoming a clinical standard of care."
"Despite these operational challenges, we continue to make important progress in attracting the support and validation of leading institutions and medical societies," added Mr. Brajer. "LipoScience is pleased to report that Mayo Clinic has successfully completed its Vantera system testing, and we are working with them to achieve 'Go Live' with clinical reporting of test results in the very near future. Additionally, the American Association of Clinical Endocrinologists (AACE) recently recommended LDL particle number (LDL-P) in their cardiovascular disease (CVD) risk factor modifications algorithm for patients with diabetes. TMAO, the diagnostic test that LipoScience has exclusive rights to commercialize from the Cleveland Clinic, has recently received broad press coverage, with a recent publication in the New England Journal of Medicine and coverage on NBC News. Moreover, the National Institutes of Health has signed a contract for a Vantera system to be used for research and clinical purposes. With these strong endorsements for our test and our platform by leading institutions and medical societies, we believe that the NMR LipoProfile test and Vantera system will become an important clinical standard of care in the future."
What kind of sales reps do they need? I'm in sales when I don't trade. I see this company as an opportunity n many ways.
The IPO blues, I am also underwater but holding LT. I have confidence in this company but will take a couple of Q's to get this rolling again. At least the CEO did not sugar coat it and told it like it was, disappointing.
They need more sales reps but I believe the technology will
Sell itself. Should see continued growth. GLTA.
I'm holding on for dear life. I bought almost 1000 shares in the 11 dollar range and still holding lol...
At these prices its almost too enticing not to give in. Hmmmm.
Hopefully they can turn it around and focus on sales reps. They have the best technology. I'm holding LT.
Had a feeling bout this. Glad I unloaded when I could. Good luck to every1
REPORTED $6.50 today
LipoScience Reports First Quarter 2013 Financial Results
GlobeNewswirePress Release: LipoScience, Inc. – Thu, May 9, 2013 4:05 PM EDT
RELATED QUOTES
Symbol Price Change
LPDX 6.50 -1.96
First Quarter 2013 NMR LipoProfile(R) Test Volumes Up 8.7% from 2012 Period
Announces Mayo Clinic Preparation for "Go Live" of Clinical Reporting on Vantera(R) System and Inclusion in American Association of Clinical Endocrinologists Diabetes Management Algorithm
RALEIGH, N.C., May 9, 2013 (GLOBE NEWSWIRE) -- LipoScience, Inc. (LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care, today announced its financial results for the first quarter ended March 31, 2013.
First Quarter Results
During the first quarter of 2013, clinicians ordered approximately 518,000 NMR LipoProfile tests, representing an increase of 8.7% over the first quarter of 2012. Total revenue was $13.6 million for the first quarter ended March 31, 2013, a decline of 1.2% compared to the first quarter ended March 31, 2012.
"We are dissatisfied with our unit growth and revenue performance, and our responses are already underway," commented Richard Brajer, President and Chief Executive Officer. "Based on a comprehensive review, the four primary factors contributing to the first quarter 2013 revenue shortfall were 1) we were unable to get the needed number of new sales representatives up and running, 2) our direct business is converting to our lab partners at a faster rate than prior years, 3) managed care headwinds, and 4) Vantera system placement delays."
"Given these factors and our slow start, we are reducing our full year 2013 revenue guidance to $54 to $56 million," said Mr. Brajer. "Unfortunately, these issues cannot be fixed overnight. But I can assure you that we fully understand what the issues are, and we are assertively implementing our responses as we continue to drive toward becoming a clinical standard of care."
"Despite these operational challenges, we continue to make important progress in attracting the support and validation of leading institutions and medical societies," added Mr. Brajer. "LipoScience is pleased to report that Mayo Clinic has successfully completed its Vantera system testing, and we are working with them to achieve 'Go Live' with clinical reporting of test results in the very near future. Additionally, the American Association of Clinical Endocrinologists (AACE) recently recommended LDL particle number (LDL-P) in their cardiovascular disease (CVD) risk factor modifications algorithm for patients with diabetes. TMAO, the diagnostic test that LipoScience has exclusive rights to commercialize from the Cleveland Clinic, has recently received broad press coverage, with a recent publication in the New England Journal of Medicine and coverage on NBC News. Moreover, the National Institutes of Health has signed a contract for a Vantera system to be used for research and clinical purposes. With these strong endorsements for our test and our platform by leading institutions and medical societies, we believe that the NMR LipoProfile test and Vantera system will become an important clinical standard of care in the future."
Additional First Quarter Operating Results
For the first quarter ended March 31, 2013, gross profit was $10.8 million compared to $11.5 million in the prior year, a decrease of 6.1%. Gross margin for the first quarter of 2013 was 79.1%, as compared to 83.2% for the first quarter of 2012 due primarily to increased costs incurred in 2013 associated with the launch of the Vantera system at third-party customer sites.
The overall average selling price of NMR LipoProfile tests decreased 6.4% to $25.25 for the first quarter of 2013, compared to $26.99 for the prior year period. The decline was primarily the result of certain reductions in price for some clinical laboratory customers based on their achievement of higher test volumes set forth in their agreements as well as the continuing shift in channel mix toward high-volume clinical laboratory customers. The percentage of total NMR LipoProfile tests sold through the Company's direct distribution channel, whereby clinicians ordered the test directly from LipoScience, decreased from 6% for the first quarter ended March 31, 2012 to 3% for the first quarter ended March 31, 2013. This trend reflects the Company's strategy of increasing the proportion of its business conducted through clinical diagnostic laboratories, resulting in an overall increase in test volumes, but a decreasing average selling price due to the shift in channel mix.
During the first quarter of 2013, sales and marketing expenses of $6.7 million were up 19.6% compared to $5.6 million in the prior year period. Sales and marketing expenses represented 48.9% of total revenues for the first quarter of 2013 compared to 40.4% in the first quarter of 2012. The increase in sales and marketing expenses as a percentage of revenue for the first quarter of 2013 is due to the continued expansion of the Company's direct sales force, growing geographic presence and an expansion in the Health, Policy & Reimbursement organization. These increases were partially offset by lower marketing expenses experienced during the first quarter of 2013 as a result of the timing of various marketing programs and medical education initiatives to drive awareness and adoption of the NMR LipoProfile test.
For the first quarter ended March 31, 2013, research and development expenses of $3.1 million increased by 45.9% as compared to $2.1 million during the prior year period. As a percentage of total revenues, research and development expenses increased to 23.0% for the first quarter of 2013, compared to 15.6% for the first quarter of 2012. This increase over the prior year period primarily reflects higher personnel-related expenses due to increased headcount, higher consulting fees for external research and development studies in support for our publication efforts, and other engineering projects, as well as higher allocated information technology and facility charges.
General and administrative expenses in the first quarter of 2013 were $3.3 million, up 47.0% compared to $2.3 million in the first quarter of 2012.The increase versus the prior year period resulted primarily from higher fees associated with the expansion of our business operations, compliance obligations in connection with becoming a publicly traded company and increased salaries and benefits due to higher staffing levels. The Company also incurred $0.3 million in tax liability as a result of the new U.S. medical device tax that became effective in January 2013 and that applies to sales of the NMR LipoProfile test. These higher costs were partially offset by lower bad debt expense. General and administrative expenses represented 24.3% of total revenues for the first quarter of 2013 compared to 16.3% in the first quarter of 2012.
Net loss for the first quarter of 2013 was $2.8 million compared to net income of $1.3 million in the prior year period.
As of March 31, 2013, LipoScience had approximately $55.0 million of cash and cash equivalents and $15.7 million of long-term debt. In the initial public offering, or IPO, completed in January 2013, LipoScience raised net proceeds of $44.4 million after the underwriting discount and offering expenses. Contemporaneous with the closing of the IPO, the Company paid $5.2 million in accrued dividends to holders of the Company's Series F preferred stock, which converted into common stock upon the closing of the IPO. In the first quarter, LipoScience also paid off the outstanding balance of $5.0 million on the Company's revolving line of credit.
Full Year 2013 Revenue Outlook
Based on information available as of May 9, 2013, the Company expects that total revenue for the full year 2013 will range from approximately $54 to $56 million as compared to reported revenue of $54.8 million for the full year 2012.
Conference Call Information
LipoScience management will host a conference call today at 4:30 p.m. EDT to discuss the first quarter 2013 financial results. To participate in the call, please dial (877) 303-2523 (U.S. and Canada) or (253) 237-1755 (international). A live webcast will be available on the Investor Relations section of the corporate website at http://investor.liposcience.com.
A replay of the conference call will be available beginning May 9, 2013 at 7:30 p.m. EDT and ending on May 21, 2013 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 60327831. A replay of the webcast will be available on the corporate website for two weeks, through May 21, 2013.
About LipoScience, Inc.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, the Vantera(R) system, has been cleared by the FDA. It requires no previous knowledge of NMR technology to operate and has been designed to significantly simplify complex technology through ease of use and walk-away automation. The Vantera system will be placed with national and regional clinical laboratories.
LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.
Yes sir. I had to get those cheapies yesterday.
Looking right for another run.
Almost time to get back in
LipoScience, Inc. (Nasdaq:LPDX) today announced that it will release its first quarter of fiscal year 2013 financial results after the market close on Thursday, May 9, 2013. An investor conference call will follow on the same day at 4:30 P.M. ET.
Hang on till next week, more to come.
That was the quickest $100 I've made in a while. Catch you on the next turn.
Nice call, you will not be disappointed. Going back to $9.50.
It is gettn attention from sum where. I took a small position at 8.49.
Keep an eye on this company and the next Q report. Could make you a believer in a position. It is now below IPO price.
I actually stumbled upon this on accident. The more dd the more intrigued.
My own DD on this company and the shift toward their testing science, which is much more accurate. I recommend this stock and the next Q report will solidify my stance on a position LT. IMO
What brought you here my friend?
Something must have sparked your interest to question mine.
What brought you here and what is your interest? There really isnt enough data to confirm a position.
LipoScience to Release Fourth Quarter and Fiscal Year 2012 Financial Results
LipoScience, Inc. (Nasdaq:LPDX) today announced that it will release its fourth quarter and fiscal year 2012 financial results after the market close on Wednesday, March 27, 2013. An investor conference call will follow on the same day at 4:30 P.M. ET.
The conference call will be hosted by Richard O. Brajer, President and Chief Executive Officer, and Lucy G. Martindale, Executive Vice President and Chief Financial Officer.
To participate in the call, please dial (877) 303-2523 (U.S. and Canada) or (253) 237-1755 (international). A live webcast will be available on the Investor Relations section of the corporate website at http://investor.liposcience.com.
A replay of the conference call will be available beginning March 27, 2013 at 7:30 p.m. ET and ending on April 10, 2013 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 20052954. A replay of the webcast will be available on the corporate website for two weeks, through April 10, 2013.
About LipoScience, Inc.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the FDA. It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk away automation. The Vantera system will be placed with national and regional clinical laboratories.
LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
45
|
Created
|
02/01/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |